[verwijderd] 8 februari 2007 09:17 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:aextracker schreef:Jaarcijfers Orthovita gisteren bekend > 35% omzetgroei over 2006.ISOTIS moet zijn weg nog vinden. Nog geen "droomscenario" tot op heden t.g.v. de beursgang op de NASDAQ.TrackerIsotis beloofde 25% op jaarbasis en zal daar ook op uitkomen.Hoeveel extra eenmalige verkoop van onderdeel baten zitten er bij Ortho in? Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 8 februari 2007 10:10 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 ortho is drukWed, Feb 7, 2007 • Orthovita Taps Pavucek As CFOAP (Wed 7:53pm) • Orthovita names CFO Joseph Paiva as chief business officerat Reuters (Wed 7:17pm) • Orthovita Announces Appointment of Chief Business Officer and Chief Financial OfficerBusiness Wire (Wed 7:00pm) • ORTHOVITA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 8 februari 2007 20:20 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Beweging genoeg.www.prnewswire.com/cgi-bin/stories.pl...Vriendelijke groet. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 21 februari 2007 09:21 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Associated PressNuVasive 4Q Loss NarrowsAssociated Press 02.20.07, 6:03 PM ETRelated Quotes NUVA 23.94 + 0.00 NUVA 23.94 + 0.00 Medical device maker NuVasive Inc. said late Tuesday its fourth-quarter loss narrowed as revenue jumped 62 percent.The company lost $2.7 million, or 8 cents per share, compared with a loss of $4.2 million, or 17 cents per share, during the same period a year prior. Revenue rose to $30.5 million from $18.8 million.Analysts polled by Thomson Financial expected a loss of 11 cents per share on revenue of $27.2 million.NuVasive (nasdaq: NUVA - news - people ) said it started to realize cost savings during the fourth quarter from the buyout of Pearsalls Ltd., which related to the NeoDisc device and technology. The $33.1 million deal eliminated royalty obligations and potential milestone payments.For the full year, the company lost $47.9 million, or $1.47 per share, compared with a loss of $30.3 million, or $1.24 per share, in 2005. Revenue rose to $98.1 million from $62.6 million.Shares of NuVasive rose 61 cents, or 2.6 percent, to close at $23.94 on the Nasdaq Stock Exchange. The stock has traded between $15.14 and $25.29 over the last 52 weeks. In aftermarket action, the stock rose 46 cents.Copyright 2006 Associated Press. All rights reserved. This material may not be published broadcast, rewritten, or redistributed Met vriendelijke groet. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 21 februari 2007 16:34 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 www.ryortho.com/NEWSSHORTS/volume3/is...Groet. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 21 februari 2007 16:42 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:wishdom schreef:www.ryortho.com/NEWSSHORTS/volume3/is...Groet.met dank voor de info, interessant. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 21 februari 2007 19:56 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Osteotech Inc. Unveils Plexur™ at Academy Meeting By Robin Young February 21, 2007 At the Academy meeting last week, Osteotech introduced its first FDA-cleared product produced under the Plexus technology platform. The product, Plexur ™, is an osteoconductive, bone/polymer biocomposite manufactured under Osteotech's proprietary Plexus Technology Platform. It is a porous, resorbable scaffold that can be used to fill bone voids of the pelvis and extremities.Plexur™ P is an osteoconductive biocomposite of cortical mineralized bone fibers suspended in a resorbable porous polymer scaffold that has demonstrated controlled remodeling and resorption characteristics. Plexur P uses overlapping bone fibers with interconnected pores, which simulate bone structure, to facilitate absorption of blood and allowing multiple pathways for bone forming cells to begin the remodeling process. Plexur P will initially be available as granules and cylindrical plugs, but ultimately, will be available in multiple forms including blocks, wedges, and sheets.Osteotech is positioning Plexur P to compete against osteoconductive synthetic bone void fillers. On a worldwide basis, Osteotech controls over 17 patents and over 68 pending patent applications covering the Plexus Technology for human and xenograft bone tissue. Met vriendelijke groet. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 22 februari 2007 14:42 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Osteotech is anderhalve week terug flink gestegen (bijna 40% in een paar dagen tijd onder hoog volume). Voorkennis? Aanbevelingen 0 ” Quote Reageren Niet oké
aextracker 22 februari 2007 16:52 auteur info aextracker Lid sinds: 23 feb 2006 Laatste bezoek: 07 jun 2024 Aanbevelingen Ontvangen: 8882 Gegeven: 1662 Aantal posts: 13.755 Hoop doet leven. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 28 februari 2007 08:19 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 www.debeurs.nl/Forum/topic.asp?forum=... Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 28 februari 2007 11:45 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Orthovita Completes Patient Enrollment in Cortoss® Study By Elizabeth Hofheinz, MEd, MPH February 26, 2007 Patients routinely help companies march toward the FDA finish line. For spine and orthopedic biosurgery company Orthovita Inc., it is no different. The company is reporting the completion of patient enrollment for its pivotal, prospective, randomized study for Cortoss® Bone Augmentation Material in development for the treatment of vertebral compression fractures. The study, involving 256 patients, is being conducted under an FDA investigational device exemption (IDE) and is designed to assess the safety and efficacy of Cortoss for the treatment of osteoporotic vertebral compression fractures compared to polymethylmethacrylate (PMMA) bone cement. Randomization is approximately 2:1 (162 patients treated using Cortoss® and 94 patients treated using a PMMA bone cement) at 22 sites. Outcomes are being measured by the Visual Analog Scale (VAS), Oswestry Disability Index (ODI), SF-12 Health Survey, and maintenance of height and alignment at the level(s) treated. To be eligible for the study, patients must have had an osteoporotic compression fracture at one or two levels and a minimum VAS score of 50, a minimum ODI score of 30%, the presence of edema on MRI or bone scan, and other eligibility criteria. Exclusionary criteria include greater than 70% collapse of vertebrae, spinal canal compromise, neurologic deficit at the level(s) to be treated, or tumors. In the news release, Dr. Erik Erbe, chief science officer of Orthovita, stated, "We appreciate the recruitment efforts of our dedicated clinical investigators and their diligent study coordinators for the Cortoss study. We anticipate that their work in the study will yield sufficient data for analysis and ultimate submission to the FDA.” Added Antony Koblish, president and chief executive officer of Orthovita, "The completion of enrollment in this trial is a major milestone for Orthovita and an important event in the effort to understand and treat vertebral compression fractures of the spine. Pending regulatory clearance, Cortoss is positioned to be the first new proprietary biomaterial implant for the treatment of vertebral compression fractures and an alternative to PMMA bone cements available today." Those in the EU can take advantage of Cortoss, as it has CE Certification for screw augmentation and for vertebral augmentation. Thus Cortoss can not only be sold in the European Union, but in other countries that have adopted the Union's regulatory standards. Cortoss® is not available for sale in the U.S. and is limited to investigational use. Met vriendelijke groet. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 28 februari 2007 15:17 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Onderdeel van RTIX.Vinden jullie dit soor nieuws leuk om te lezen,of liever toch maar niet.Tissue Regeneration Technologies and Nonvasiv to Merge WOODSTOCK, Ga.--(BUSINESS WIRE)--Tissue Regeneration Technologies, LLC (TRT) and Nonvasiv, LLC (Nonvasiv) are pleased to announce they have agreed to merge, subject to certain conditions and due diligence by both parties. This is a merger between the strategic and the tactical. TRT is largely focused on long-term value for its investors by investing in research and development, clinical studies, and relationships. TRT has raised approximately $10 million in private equity since its inception for these purposes. Nonvasiv is capitalizing on business segments, such as the veterinary market, that are immediately profitable. “This merger is the ideal convergence of time, talent, and technology,” stated TRT president, John Warlick. This merger will result in: a combination of industry leading intellectual property portfolios; expansion of TRT’s existing product line with low-cost, portable technology by Nonvasiv; cost synergies to exceed $15 million in manufacturing, R&D and regulatory; joint marketing and sales forces with regional and complimentary market segments; and the most talented and experienced staff in shockwave medicine and technology working together. Upon completion of the merger, TRT will offer a line of new, non patent-infringing shockwave products to the veterinary field, including a device that offers the full spectrum of lens assemblies to best treat all equine and small animal indications. In addition to offering focused, planar and unfocused shockwaves, this new technology substantially extends the industry standard for consumable shock life. Unlike current industry standards, Nonvasiv’s patented new treatment head does not require the use of heavy metal catalysts and thus provides a more environmentally friendly solution in veterinary medicine. TRT has also entered into negotiations, with a third party independent of Nonvasiv, to acquire the rights to a replacement disposable for the existing veterinary market, which have generated revenues in excess of $3.0 million annually. This disposable will upgrade existing devices to TRT’s new long life and environmentally friendly technology. “Another advantage to this merger is the cost savings to be realized by Nonvasiv. Historically, our manufacturing operations have been outsourced, however by utilizing the exceptional experience and know-how of TRT’s manufacturing subsidiary, MTS Europe GmbH, we will gain huge cost benefits,” stated Dr. Jens Stabler, CEO of Nonvasiv. Additionally, we are extremely pleased to announce that Dr. Carlos Leal, OrthoWave Colombia (OWC), the premier shockwave device distributor in South America has agreed to distribute the group’s veterinary products in Mexico, Central and South America. About TRT TRT is a leading-edge health care company that believes in “doing well by doing good.” Our state-of-the-art medical devices utilize MultiWaveTM technology (a combination of heat, electromagnetic, acoustic, and light energies) to provide non-invasive and minimally invasive treatment for numerous pathological conditions, including chronic wounds, multiple periodontal applications, pseudoarthrosis and other avascular conditions of the bone, and ischemic heart disease. TRT is headquartered in suburban Atlanta, Georgia from which we operate our urology division, Shockwave Technical Service, and our cardiac subsidiary, Cardiac Regeneration Technologies. Production of our devices is handled by TRT’s manufacturing subsidiary, MTS Europe GmbH, located in Lake Constance, Germany. TRT has FDA clearance to market its LithoGoldTM lithotripsy system for treatment of kidney and ureteral stones. Our devices are currently CE approved and distributed in approximately 20 countries throughout North America, Europe, Asia, Africa and South America. For more information, please visit the company’s website at www.trtllc.com. About Nonvasiv Nonvasiv was formed by the founders and owners of SwiTech Medical, AG (Switzerland) and ITS, LLC (USA/Germany). Over the past two years these companies have jointly developed a new generation, low-cost, portable shockwave device. Last year over 60 devices were sold in Europe, Asia and South America. To commercialize this product on a broader scale and to combine respective know-how, client networks and IP rights, Nonvasiv, LLC was formed. Nonvasiv, LLC is located in Kennesaw, Georgia and its subsidiary Nonvasiv, GmbH is located in Konstanz, Germany. Nonvasiv’s core strengths lie in technology, marketing and sales in the medical and veterinary businesses in Europe and the US. Nonvasiv’s management team has more than 75 years of experience in the shock wave business. Our R&D team includes the original developers of the successful VersaTron®/EvoTron® product line. We are now launching the next generation shockwave device to reaffirm our leadership position in this technology. To better serve the needs of the dermatology and companion animal markets, Nonvasiv has also developed and patented a flat wave treatment head. This is a major advancement in shockwave medicine which offers pain free treatment of current indications, while providing opportunity for a wider spectrum of new applications, the most immediate being companion animal medicine. For more information, please visit the company’s website at www.nonvasiv.de. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 28 februari 2007 15:24 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Associated PressAlphatec Shares Rise on Sales ResultsAssociated Press 02.23.07, 12:02 PM ETRelated Quotes ATEC 4.58 + 0.00 NDAQ 30.30 + 0.00 Shares of medical device maker Alphatec Holding Inc. jumped in midday trading Friday following the company's positive fourth-quarter sales results and 2007 guidance.The stock gained 36 cents, or 9.1 percent, to $4.30 per share on the Nasdaq Stock Market (nasdaq: NDAQ - news - people ). Shares have traded between $2.77 and $8.80 over the last 52 weeks.The company, despite a wider loss on one-time charges, beat Wall Street expectations for sales and set sales guidance for 2007 at a 12 percent to 15 percent increase. It expects 2007 revenue between $83 million and $85 million, mainly from surgeons using its products, new products and higher licensing revenue.RBC Capital Markets analyst Phil Nalbone reaffirmed a "Outperform" rating with a $8 price target for the company citing the jump in fourth-quarter sales. Alphatec makes spine surgery implants used to treat spine disorders."The upside surprise reflects significant improvement in the productivity of the direct sales force and distributor network after sloppy expansion had undermined third-quarter performance," he wrote in a note to investors.He also raised sales guidance for 2007 to $85.6 million from $83.3 million, citing the company's outlook. Another positive giving the company a fourth-quarter boost was the licensing agreement with Scient'X. Alphatec plans to launch 12 new products in 2007.ThinkEquity Partners analyst Stephan Ogilvie reaffirmed his "Source of Funds" rating with a $4 price target and took a more cautious outlook on the news."Most of the concerns highlighted in our previous notes still exist," he said, citing litigation, revenue concentration, doctor incentives and high administrative costs.But sales force problems seem to be on the mend, he wrote in a note to investors, and new executives with experience in the spine industry are a marked improvement.The company changed its chief executive and chief financial officer during the fourth quarter."We think the spine market is very attractive and a company that executes well is likely to grow faster than the market, so the potential exists, but our concerns over leadership, litigation, details of the Scient'X deal, and other issues keep us cautious," Ogilvie said.Copyright 2006 Associated Press. All rights reserved. This material may not be published broadcast, rewritten, or redistributed Groet. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 28 februari 2007 15:29 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Vinden jullie dit soor nieuws leuk om te lezen,of liever toch maar niet?Je doet leuk mee Wishdom,ga zo door.Ik lees het graag. Aanbevelingen 1 ” Quote Reageren Niet oké
[verwijderd] 28 februari 2007 15:39 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:mik68 schreef:Vinden jullie dit soor nieuws leuk om te lezen,of liever toch maar niet?Je doet leuk mee Wishdom,ga zo door.Ik lees het graag.Daar ben ik blij om,heb er niet zoveel verstand van,maar nieuws zoeken kan ik hartstikke goed.Met vriendelijke groet. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 28 februari 2007 15:43 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:wishdom schreef:The company, despite a wider loss on one-time charges, beat Wall Street expectations for sales and set sales guidance for 2007 at a 12 percent to 15 percent increase.Kijk, net als Isotis een hoger verlies door eenmalige zaken, maar het aandeel stijgt toch (met een lagere sales increase).PS: Wish, vooral doorgaan hiermee inderdaad! Bvd Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 28 februari 2007 17:13 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 mijn waardering voor het zoekwerk .. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 2 maart 2007 16:12 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Alphatec Holdings, Inc. Announces Fourth Quarter and Fiscal 2006 Financial ResultsMarch 2, 2007 - 7:30 AM 2006 Revenue Increased 75% - - 2007 Revenue Guidance of $83 Million to $85 Million - CARLSBAD, Calif., Feb. 22 /PRNewswire-FirstCall/ -- Alphatec Holdings, Inc. (NASDAQ:ATEC) , a spinal device company, announced today financial results for the fourth quarter and fiscal year ended December 31, 2006. Fourth Quarter and Fiscal 2006 Highlights * Annual revenues increased to $74.0 million; up 75% from 2005 * Q4:06 revenues increased to $19.2 million; up 23% from Q4:05 * Q4:06 gross margin was 68.1%; up from 55.5% from Q4:05 * Management restructuring seamless * Initial public offering Revenue in the fourth quarter of 2006 increased 23% to $19.2 million compared to $15.6 million in the fourth quarter of 2005. This represented an 11% increase from the $17.4 million reported in the third quarter of 2006. Revenue for fiscal 2006 of $74.0 million was up 75% over fiscal 2005. Gross profit for the fourth quarter of 2006 was $13.1 million with a gross margin of 68.1%, compared with a gross profit of $8.6 million with a gross margin of 55.5% in the fourth quarter of 2005. The improved margins were primarily due to the increased sales volume and lower inventory provisions. For the third quarter of 2006, gross profit was $10.8 million with a gross margin of 61.9%. Gross margin was 65.3% for the total year 2006, up from 58.1% for the total year 2005. "Our business is strong and growing as evidenced by our 75% increase in year-over-year revenue," stated John H. Foster, Chairman, President, and CEO. "The fourth quarter realignment of the senior leadership team, including the appointment of Ross Simmonds as Chief Operating Officer, has had a positive impact on the sales force and the entire organization. It has been seamless with respect to operating results." Mr. Foster added, "The Scient'x license agreement, which we announced last month, will allow us to aggressively grow in the dynamic stabilization market and leverage our current fusion business." Total operating expenses were $22.7 million in the fourth quarter of 2006, compared to $13.0 million in the 2005 fourth quarter and $16.4 million in the 2006 third quarter. The increase from 2005 was principally due to one-time severance costs and higher selling costs and commissions on our higher volume. For total year 2006, operating expenses were $70.4 million versus $39.6 million in 2005. Higher operating expenses were primarily due to higher selling costs on the increased volume and build out of the Company's infrastructure. The net loss for the fourth quarter of 2006 was $11.3 million, or $(0.34) loss per share, compared to $8.4 million, or $(0.45) loss per share, in the fourth quarter of 2005. For fiscal 2006, the net loss was $29.3 million, or $(1.08) loss per share as compared to $21.7 million, or $(1.19) loss per share, for fiscal 2005. Earnings before interest, taxes, depreciation, amortization ("EBITDA"), and adjusted for other significant items, were a positive $0.4 million for the fourth quarter 2006 on $19.2 million of revenue. The cash balance at December 31, 2006, was $18.0 million, which includes restricted cash. This is a decrease of $3.4 million from the September balance. 2007 Guidance Alphatec's revenue guidance for fiscal 2007 is $83 million to $85 million based on additional surgeons using our products, the release of new products and increasing Scient'x license revenues as the year progresses. The Company's guidance does not include any technology acquisitions subsequent to the recently announced Scient'x license agreement. Target gross margins worldwide for 2007 are in the range of 68% to 70%, which allows management to reasonably expect a substantial and positive EBITDA for the year. Non-GAAP Information Earnings before interest, taxes, depreciation, and amortization ("EBITDA") included in this press release is a non-GAAP (generally accepted accounting principles) financial measure which represents net income (loss) excluding the effects of interest, taxes, depreciation, amortization and stock based compensation costs. EBITDA, as defined above, may not be similar to EBITDA measures used by other companies and is not a measurement under generally accepted accounting principles. The company believes that EBITDA provides useful information to investors about the company's performance because it eliminates the effects of period to period changes in costs that are not directly attributable to the underlying performance of the company's business operations. Management uses EBITDA in evaluating the overall performance of the company's business operations. Though management finds EBITDA useful for evaluating aspects of the company's business, its reliance on this measure is limited because excluded items often have a material effect on the company's earnings and earnings per common share calculated in accordance with GAAP. Therefore, management always uses EBITDA in conjunction with GAAP earnings and earnings per common share measures. The company believes that EBITDA provides investors with an additional tool for evaluating the company's core performance, which management uses in its own evaluation of performance, and a base-line for assessing the future earnings potential of the company. While the GAAP results are more complete, the company prefers to allow investors to have this supplemental metric since, with reconciliation to GAAP, it may provide greater insight into the company's financial results. Conference Call Alphatec will host a conference call today at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results. To participate in the conference call, please dial 888-338-6760 (Domestic) or 973-582-2858 (International) a few minutes before 4:30 p.m. ET on Thursday, February 22, 2007. A replay of the conference call will be available from 8:30 p.m. ET on February 22, 2007 until 11:59 p.m. ET on March 1, 2007. The replay dial in number is 877-519-4471 (Domestic) or 973-341-3080 (International). The replay pin number is 8437248. The call will also be available on the Internet live and for 90 days thereafter at the following URL: www.videonewswire.com/event.asp?id=37953 www.drugnewswire.com/13625/Iets meer info dan de vorige.Met vriendelijke groet. Aanbevelingen 0 ” Quote Reageren Niet oké
aextracker 3 maart 2007 17:54 auteur info aextracker Lid sinds: 23 feb 2006 Laatste bezoek: 07 jun 2024 Aanbevelingen Ontvangen: 8882 Gegeven: 1662 Aantal posts: 13.755 Qua omzetgroei blijft ISOT Inc. met z'n 17% dus zwaar achter op de peergroup, idem bruto marge. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 3 maart 2007 18:16 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Leuk he Tracker zo,n draadje,heb je vergelijkingsmateriaal.En je hebt het goed gezien.maar..............wat niet is kan nog komen.Ook is het raadzaam om naar het aantal uitstaande aandelen te kijken.Met vriendelijke groet. Aanbevelingen 0 ” Quote Reageren Niet oké
Beurscodes, betekenis en hulp bij zoeken Europa AEX Euronext Amsterdam BRU Euronext Brussels PSE Euronext Paris LIS Euronext Lissabon CHX CBOE Europe, grote(re) EU aandelen NAV Investment Funds (NAV) Noord-Amerika NYS New York Stock Exchange OTC CBOE BZX Exchange (US) TSE Toronto Stock Exchange Kunt u een instrument niet vinden? Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code. Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze. Waar vind ik die ISIN code? Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'. Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.